Shares of TG Therapeutics, Inc. (NASDAQ:TGTX – Get Rating) crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $6.83 and traded as high as $6.86. TG Therapeutics shares last traded at $6.59, with a volume of 1,447,417 shares.
Analyst Upgrades and Downgrades
TGTX has been the topic of a number of recent research reports. StockNews.com raised TG Therapeutics to a “sell” rating in a report on Friday, June 17th. B. Riley reduced their price target on TG Therapeutics from $23.00 to $17.00 and set a “buy” rating on the stock in a research report on Monday, June 13th. Three equities research analysts have rated the stock with a sell rating and four have assigned a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $21.25.
TG Therapeutics Stock Down 2.1 %
The company has a fifty day simple moving average of $6.83 and a 200-day simple moving average of $6.83. The company has a quick ratio of 4.68, a current ratio of 4.68 and a debt-to-equity ratio of 0.53. The firm has a market cap of $957.36 million, a P/E ratio of -3.05 and a beta of 2.19.
Institutional Investors Weigh In On TG Therapeutics
About TG Therapeutics
TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma.
- Get a free copy of the StockNews.com research report on TG Therapeutics (TGTX)
- 3 Airline Stocks Stuck in a Holding Pattern
- Roku Stock is Down but Not Out
- Is Ford Rolling To A Rebound After Its Q3 Warning
- If You’re Hungry for Value, Take a Bite on Ruth’s Hospitality Grp
- Has AMD stock stock fallen too far?
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.